Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716889 | 0.86 | MAPK1 (0.62) | ALDH1A1HPGDKMT2ARAB9AFAAH | |
| SCHEMBL515153 | 0.84 | TGM2 (0.60) | GAAALDH1A1HPGDTGM2KMT2A | |
| SCHEMBL31287149 | 0.83 | HPGD (0.68) | GAAALDH1A1HPGDTGM2KMT2A | |
| SCHEMBL29895464 | 0.83 | GAA (0.55) | GAAEGFRALDH1A1HPGDTGM2 | |
| SCHEMBL30599548 | 0.83 | MAPT (0.66) | GAAEGFRALDH1A1HPGDRAB9A | |
| SCHEMBL515034 | 0.83 | GAA (0.55) | GAAEGFRALDH1A1HPGDTGM2 | |
| SCHEMBL1400198 | 0.83 | GAA (0.55) | GAAEGFRALDH1A1HPGDTGM2 | |
| SCHEMBL1188378 | 0.83 | MAPT (0.66) | GAAEGFRALDH1A1HPGDRAB9A | |
| SCHEMBL14625837 | 0.82 | GAA (0.58) | GAAEGFRALDH1A1HPGDTGM2 | |
| SCHEMBL264735 | 0.81 | GAA (0.66) | GAAEGFRALDH1A1HPGDTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| CN-115996932-A | New macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2023-04-21 | — | — | CN | disclosed |
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
| US-20160229839-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229839-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015047973-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110155660-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC | 2011-06-30 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7882963-B2 | modifying polyamide discriminating layer ( e.g metaphenylene diamine- trimesoyl chloride monomers) with aminoacetophenone or aminothiophenol; fouling resistant surface, improved salt rejection, antimicrobial properties, improved solute, and/or small organics rejection; for water purification | DOW GLOBAL TECHNOLOGIES INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090159527-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC | 2009-06-25 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101103012-A | Compounds modulating PPAR gamma type receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2008-01-09 | — | — | CN | disclosed |
| WO-2007133362-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | GAA 3982/4885EGFR 3297/4885ALDH1A1 412/4885 |
| US-20160229839-A1 | Factor XIa Inhibitors | F11, SERPINC1, TFPI | GAA 2418/4885EGFR 1705/4885ALDH1A1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.